![]() |
市場調查報告書
商品編碼
1370621
肌肉鬆弛藥物市場 - 按藥物類型(骨骼肌鬆弛藥物)、劑型(片劑、膠囊)、應用(肌肉痙攣和止痛)、給藥途徑(口服)、配銷通路(醫院藥房)、2023年全球預測- 2032Muscle Relaxant Drugs Market - By Drug Type (Skeletal Muscle Relaxant Drugs), Dosage Form (Tablet, Capsule), Application (Muscle Spasm & Pain Relief), Route of Administration (Oral), Distribution Channel (Hospital Pharmacy), Global Forecast 2023-2032 |
2023年至2032年,全球肌肉鬆弛藥物市場將以6.4%的年複合成長率成長。人口老化導致肌肉骨骼疾病和病症的發生率增加,推動肌肉鬆弛藥物業務的發展。
此外,壓力水平的上升和久坐的生活方式導致肌肉相關問題激增,進一步促進了該行業的成長。人們越來越認知到這些藥物在疼痛管理方面的功效,以及將治療應用擴展到肌肉骨骼疾病之外,將推動業務成長。
新穎配方的引入和對非成癮替代品的追求也有望推動市場擴張。 2022 年 6 月,Amneal Pharmaceuticals 推出了 LYVISPAH,這是一種含有巴氯芬的創新口服顆粒藥物,已獲得美國 FDA 批准,用於治療與多發性硬化症和各種脊髓疾病等疾病相關的痙攣。
市場根據藥物類型、劑型、應用、給藥途徑、配銷通路和地區進行分類。
根據藥物類型,到2032 年,臉部肌肉鬆弛藥物領域的年複合成長率將達到5.7%,這主要得益於對非侵入性整容手術的需求不斷成長、對美容的日益偏好以及臉部年輕化技術的進步。此外,尋求臉部肌肉放鬆療程的老化人口不斷增加將促進該領域的成長。
在易於給藥、更快起效和改善患者依從性等因素的推動下,液體劑型部分在分析期間將呈現 6.1% 的年複合成長率。液體製劑因其方便和更快的治療效果而受到優選。
到 2032 年,手術應用領域的年複合成長率將達到 5.7%。外科手術(包括微創手術)的增加將推動手術用肌肉鬆弛藥物的業務。外科醫生依靠肌肉鬆弛劑來提高手術精度和患者安全,從而推動市場擴張。
從地區來看,在人口老齡化、肌肉骨骼疾病患病率上升、醫療基礎設施不斷完善以及對治療選擇意識不斷增強的推動下,亞太地區肌肉鬆弛藥物行業預計在2023 年至2032 年期間將以7.3% 的年複合成長率成長。此外,製藥創新和擴大醫療保健服務範圍將促進該地區的業務成長。
The global muscle relaxant drugs market will grow at a 6.4% CAGR from 2023 to 2032. An aging population is experiencing an increased incidence of musculoskeletal disorders and conditions, driving the business for muscle relaxant medications.
Additionally, rising stress levels and sedentary lifestyles contribute to a surge in muscle-related issues, further boosting the industry's growth. The growing awareness of the efficacy of these drugs in pain management and the expansion of therapeutic applications beyond just musculoskeletal disorders will drive business growth.
The introduction of novel formulations and the pursuit of non-addictive alternatives are also anticipated to fuel market expansion. In June 2022, Amneal Pharmaceuticals introduced LYVISPAH, an innovative oral granules medication containing baclofen, which has received approval from the USFDA for the treatment of spasticity associated with conditions such as multiple sclerosis and various spinal cord disorders.
The market is categorized based on drug type, dosage form, application, route of administration, distribution channel, and region.
Based on drug type, the facial muscle relaxant drug segment will record a 5.7% CAGR through 2032, driven by the rising demand for non-invasive cosmetic procedures, growing preference for aesthetic enhancements, and advancements in facial rejuvenation technologies. Moreover, rising aging population seeking facial muscle relaxation treatments will foster growth in the segment.
The liquid dosage form segment will exhibit a 6.1% CAGR during the analysis period, driven by factors such as ease of administration, faster onset of action, and improved patient compliance. Liquid formulations are preferred for their convenience and quicker therapeutic effects.
The surgery application segment will reflect a 5.7% CAGR through 2032. Increasing surgical procedures, including minimally invasive surgeries will drive the business of muscle relaxant drugs for surgery. Surgeons rely on muscle relaxants to enhance surgical precision and patient safety, driving market expansion.
Regionally, the Asia Pacific muscle relaxant drugs industry is anticipated to grow at a 7.3% CAGR during 2023-2032, driven by the aging population, rising prevalence of musculoskeletal disorders, increasing healthcare infrastructure, and a growing awareness of treatment options. Moreover, pharmaceutical innovation and expanding healthcare access will augment business growth in the region.